Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients
Table 2
Associated risk factors for major adverse drug reactions due to anti-TB drugs.
Variables
Without ADRs 671 (100%)
With major ADRs 54 (100%)
Adjusted odds ratio (95% CI)
value
Age (years)
≥50
296 (44.1)
33 (61.1)
1.99 (1.13–3.51)
0.0223
<50
375 (55.9)
21 (38.9)
Gender
Female
327 (47.8)
35 (64.8)
1.94 (1.09–3.46)
0.0241
Male
344 (51.3)
19 (35.2)
Location
Urban
382 (56.9)
30 (55.6)
0.94 (0.54–1.65)
0.8868
Rural
289 (43.1)
24 (44.4)
Nationality
Iranian
522 (77.8)
49 (90.7)
2.79 (1.10–7.15)
0.0362
Immigrant (Afghans)
149 (22.2)
5 (9.3)
HIV status
HIV+
7 (1.1)
3 (5.6)
5.58 (1.40–22.23)
0.0323
HIV−
664 (98.9)
51 (94.4)
Smoking
Smoker
112 (16.7)
19 (35.2)
2.71 (1.43–5.09)
0.002
Nonsmoker
559 (83.3)
35 (64.8)
Addiction
Addict
24 (3.6)
5 (9.3)
0.36 (0.13–0.99)
0.0569
Nonaddicts
647 (96.4)
49 (90.7)
Diagnosis delay
≤30 days
269 (40.1)
23 (42.6)
0.90 (0.52–1.58)
0.7735
>30 days
402 (59.9)
31 (57.4)
TB treatment history
Primary
660 (98.4)
50 (92.6)
4.8 (1.48–15.62)
0.0203
Retreatment
11 (1.6)
4 (7.4)
Type of TB
Pulmonary
509 (75.9)
36 (66.7)
0.64 (0.35–1.15)
0.1416
Nonpulmonary
162 (24.1)
18 (33.3)
Comorbidity (except HIV)
Yes
160 (23.9)
25 (46.3)
2.75 (1.57–4.84)
0.0005
No
511 (76.1)
29 (53.7)
Grading of sputum smear
<2+
129 (39.7)
11 (33.3)
0.76 (0.36–1.62)
0.5756
≥2+
196 (60.3)
22 (66.7)
Diagnostic delay: time interval between the onset of symptoms and labelling of the patient as a tuberculosis patient. WHO grading scale for AFB found by Ziehl-Neelsen smear microscopy:scanty, 1+, 2+, and 3+.
